Literature DB >> 17024758

Prognostic variability among nonsmall cell lung cancer patients with pathologic N1 lymph node involvement. Epidemiological figures with strong clinical implications.

Adele Caldarella1, Emanuele Crocetti, Camilla E Comin, Alberto Janni, Andrea Lopes Pegna, Eugenio Paci.   

Abstract

BACKGROUND: Patients who have nonsmall cell lung cancer with N1 lymph node status are an intermediate group of patients who have a variable prognosis. Differences in lymph node level (hilar or pulmonary lymph nodes) may influence patient survival. The authors retrospectively analyzed the factors that influenced prognosis, including the level of N1 lymph node involvement.
METHODS: The authors used the Tuscan Cancer Registry archives to retrieve records on 2523 patients who had lung tumors diagnosed during the period from 1996 and 1998 in the provinces of Florence and Prato, central Italy. To analyze the survival of patients according to the level of lymph node involvement, the prognoses of patients with nonsmall cell lung cancer who had N1 lymph node status were compared in a population-based case series. Among 112 patients with pathologic N1 status, the following variables were analyzed for their influence on postoperative survival: gender, age, cell type, pathologic tumor status, the number of metastatic lymph nodes, the level of metastatic lymph nodes (hilar or pulmonary), and the type of surgical resection.
RESULTS: The 5-year survival rates for patients who had involvement of pulmonary and hilar lymph nodes were 41.2% and 21.8%, respectively (P =.005). A Cox proportional hazards model analysis indicated that the presence of hilar lymph node involvement was an independent prognostic factor.
CONCLUSIONS: N1 pathologic lymph node status was identified in a combination of subgroups with different prognoses, and the presence of hilar lymph node disease had prognostic significance. This difference in survival may lead to the use of different therapies for these subgroups of patients with pathologic N1 non-small cell lung cancer.

Entities:  

Mesh:

Year:  2006        PMID: 17024758     DOI: 10.1002/cncr.22072

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Intrapulmonary lymph node retrieval: unclear benefit for aggressive pathologic dissection.

Authors:  Christina Brzezniak; Giuseppe Giaccone
Journal:  Transl Lung Cancer Res       Date:  2012-12

2.  Differential prognostic significance of extralobar and intralobar nodal metastases in patients with surgically resected stage II non-small cell lung cancer.

Authors:  John C Haney; Jennifer M Hanna; Mark F Berry; David H Harpole; Thomas A D'Amico; Betty C Tong; Mark W Onaitis
Journal:  J Thorac Cardiovasc Surg       Date:  2014-01-02       Impact factor: 5.209

3.  Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis.

Authors:  Qian Li; Ping Zhan; Dongmei Yuan; Tangfeng Lv; Alexander Sasha Krupnick; Antonio Passaro; Alessandro Brunelli; Matthew P Smeltzer; Raymond U Osarogiagbon; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2016-06

4.  Anatomical location and number of metastatic lymph nodes for prognosis of non-small cell lung cancer.

Authors:  Joji Samejima; Hiroyuki Ito; Takuya Nagashima; Daiji Nemoto; Daisuke Eriguchi; Haruhiko Nakayama; Norihiko Ikeda; Morihito Okada
Journal:  J Thorac Dis       Date:  2021-07       Impact factor: 2.895

5.  Detection of lymph node metastasis in lung cancer patients using a one-step nucleic acid amplification assay: a single-centre prospective study.

Authors:  María Escalante Pérez; María Teresa Hermida Romero; Begoña Otero Alén; Mónica Álvarez Martínez; Ricardo Fernández Prado; Mercedes de la Torre Bravos; Ángel Concha López
Journal:  J Transl Med       Date:  2019-07-22       Impact factor: 5.531

Review 6.  Updated Prognostic Factors in Localized NSCLC.

Authors:  Simon Garinet; Pascal Wang; Audrey Mansuet-Lupo; Ludovic Fournel; Marie Wislez; Hélène Blons
Journal:  Cancers (Basel)       Date:  2022-03-09       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.